Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?

Leukemia. 2023 Dec;37(12):2517-2519. doi: 10.1038/s41375-023-02051-3. Epub 2023 Oct 10.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use
  • Azacitidine / therapeutic use
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Myelodysplastic Syndromes* / drug therapy
  • Remission Induction
  • Treatment Outcome

Substances

  • Azacitidine
  • Antimetabolites, Antineoplastic